Moderna’s Covid-19 vaccine booster doses provided increased neutralising antibody titers against the SARS-CoV-2 virus and two variants of concern. Credit: Eric Garcetti.

The responses were observed against the SARS-CoV-2 virus and two variants of concern, the B.1.351 variant, which was first detected in South Africa, and the P.1 variant found in Brazil.

The mRNA-1273 Covid-19 vaccine is authorised for emergency use for active immunisation to prevent Covid-19 in adults, while mRNA-1273.351 is a booster vaccine candidate based on the B.1.351 variant.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

A multivalent booster candidate called mRNA-1273.211, a combination of mRNA-1273 plus mRNA-1273.351, is also being evaluated.

The Phase II study is assessing three ways for increasing neutralising titers in already vaccinated subjects using mRNA-1273.351, mRNA-1273.211 and 50µg mRNA-1273 booster dose.

Data from the trial showed that mRNA-1273.351 booster dose provided increased neutralising antibody titers against the B.1.351 variant than mRNA-1273 booster dose.

Furthermore, safety and tolerability profiles on administering a third booster dose of 50µg mRNA-1273 or mRNA-1273.351 were in line with those noticed following second mRNA-1273 dose in earlier trials.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The vaccine boosters were found to be well-tolerated with mild or moderately severe adverse events.

In addition, the mRNA-1273.351 vaccine had a reduced reactogenicity profile as compared to mRNA-1273 in this Phase II trial.

Moderna CEO Stéphane Bancel said: “The strong and rapid boost in titers to levels above primary vaccination also clearly demonstrates the ability of mRNA-1273 to induce immune memory.

“Our mRNA platform allows for rapid design of vaccine candidates that incorporate key virus mutations, potentially allowing for faster development of future alternative variant-matched vaccines should they be needed.”

Data from the analysis of mRNA-1273.211 is anticipated soon, the company noted.

Parallelly, the National Institutes of Health unit National Institute of Allergy and Infectious Diseases is carrying out a Phase I study of mRNA-1273.351 vaccine.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact